There is some exciting news from the Medicines Patent Pool in that Mylan have signed on to produce a generic glecaprevir/pibrentasvir. https://medicinespatentpool.org/mpp-media-post/the-medicines-patent-pool-and-mylan-sign-agreement-to-scale-up-access-to-first-generic-version-of-hepatitis-c-treatment-glecaprevir-pibrentasvir/ This is really significant for areas of Africa where the subtypes of HCV are very resistant to DAAs, for patient with renal failure and for patients who have failed one or more DAA […]
